Wegovy® (semaglutide) is part of a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are best known for supporting weight management and treating type 2 diabetes. However, researchers are now exploring whether these medications could also help people with binge eating disorder (BED). 

Here’s what we know about the benefits and risks of taking Wegovy® for binge eating disorder. 

What’s binge eating disorder?

According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) , BED is a psychiatric condition. It’s characterized by recurrent, distressing episodes of eating significantly more food than average over a short period of time (typically under two hours), accompanied by a feeling of loss of control.

BED is the most common eating disorder in the United States. Its exact cause remains unknown, although researchers believe multiple factors may contribute, including genetics and the presence of other mental health disorders. Because prevalence rates vary by age group and study methodology, estimates for adults and adolescents reflect different measurement frameworks and timeframes:

Both semaglutide groups brought average scores down into the mild or minimal range (below 17), while the other medication-only group remained in the moderate range (17 to 26).

Researchers propose that semaglutide’s appetite suppression and reward pathway regulation may be behind these positive outcomes. The medication interacts with parts of the brain involved in appetite regulation, which may limit compulsive eating. Semaglutide may also affect brain pathways involved in how rewarding (or compelling) food feels, which could help reduce cravings. Finally, semaglutide might improve metabolic health via blood sugar control and lowered cardiovascular strain. 

However, while preliminary findings are promising, overall evidence remains limited. A 2026 systematic review evaluating 12 studies on incretin-based therapies for binge eating behaviors found consistent reductions in binge symptoms. But the authors note that existing studies are constrained by small sample sizes, combined data, and limited follow-up. Larger, well-designed randomized controlled trials (RCTs) are needed to establish the clinical efficacy and safety of GLP-1 RAs for binge eating disorder.

Potential risks of Wegovy® for binge eating disorder

Due to limited research and lack of FDA approval for BED, Wegovy’s®’s safety profile for treating binge eating disorder remains unproven. GLP-1 medications show promise for reducing binge eating episodes. But treatment with weight loss drugs may introduce some psychological and psychiatric risks.

Increased restrictive eating behaviors

A 2026 review published in the Journal of Psychiatric Research found that excessive appetite suppression from GLP-1 RAs may inadvertently reinforce restrictive eating behaviors in those with a history of disordered eating. Restrictions can include severe portion limits, elimination of entire food groups, or fasting. These behaviors may follow binge eating episodes as a compensatory action, or they could trigger future episodes.

Published case reports describe instances of relapse or onset of restrictive eating disorders, including anorexia nervosa and atypical anorexia nervosa, associated with semaglutide and tirzepatide therapy. Case reports can’t establish direct causation or quantify overall incidence. However, they support the need for careful screening and ongoing monitoring for restrictive eating patterns, rapid weight loss, and signs of eating disorder relapse prior to and during treatment.

Decreased mood and emotional regulation

WHO’s spontaneous safety database, VigiBase, has identified potential signals for anxiety, depression, and the inability to feel pleasure (anhedonia) with semaglutide. However, because these databases rely on voluntary reports, they can only flag potential areas for future research. They can’t prove that the medication caused the symptoms, account for other health factors, or show how often these side effects actually occur.

Additionally, a meta-analysis of 80 clinical trials including over 100,000 participants found no increased risk of depression or other mental health side effects with GLP-1 medications compared to a placebo. In fact, many participants reported better control over emotional eating. However, these trials focused on people with diabetes and obesity rather than BED. So, doctors should still pay close attention to patients with a history of mental health conditions.

What to discuss with your healthcare specialist before taking Wegovy®

If you’re considering Wegovy® for BED, have an open conversation with your doctor. Metabolic treatments have the potential to impact eating behaviors and mental health. So, the more context you share, the better safety framework you can build together. 

Here’s some of what they might discuss with you:

• Mental health history: Share your complete psychological history, including any past or current struggles with restrictive eating, anxiety, or depression. Wegovy® may exacerbate certain mental health symptoms.
• Current medications: Disclose all prescription and over-the-counter drugs and supplements you’re taking. Wegovy® slows gastric emptying, which may affect the absorption of oral medications.
• Overall symptom picture: Discuss all symptoms you're experiencing, including eating patterns, cravings, and metabolic health markers like prediabetes or high blood pressure. Your doctor will evaluate whether a GLP-1 medication aligns with your overall health needs.
• Contraindications: Tell your doctor if you have a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), or an allergy or hypersensitivity to Wegovy®’s ingredients. These circumstances make the medication unsafe for you. 

Navigate binge eating disorder with Maven Clinic

Wegovy® is one of the more promising areas of research in binge eating disorder treatment. It works on both metabolism and the brain’s appetite signals, which may help explain why early studies suggest it could reduce binge eating symptoms more than some current treatments. 

However, the FDA doesn’t approve Wegovy® for treatment of BED, and the drug’s long-term safety profile for this specific condition remains unproven. Without proper oversight, the treatment may risk trading one disordered eating cycle (bingeing) for another (extreme restriction). 

For individuals considering off-label use, success requires a holistic approach that takes into account your full physical and psychological health. It’s important to note that evidence-based psychotherapy, particularly cognitive behavioral therapy (CBT), remains an established treatment for BED. Because GLP-1 RAs represent an investigational approach for BED, they’re not a substitute for comprehensive eating disorder assessment and specialized behavioral care. 

At Maven Clinic, our specialists look at your entire symptom picture to deliver personalized care. They’ll work with you to evaluate treatment options and decide whether Wegovy® (or an alternative) is the right path for you. 

Discover our approach to GLP-1 care.